Leerink analyst Puneet Souda lowered his price target for Illumina to $365 from $380 to reflect its lowered growth guide. The analyst reiterates an Outperform rating on the stock as he believes lower sequencing costs and competition among its customers continue to drive NovaSeq and its broader product upgrade cycle.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.